Rigel discovers and develops novel, small molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases.

• Rigel's R788 Phase 2a Results Published in Arthritis and Rheumatism
  
  
• Rigel Announces Third Quarter 2008 Financial Results and Clinical Update
  
  
• Rigel Initiates Two Phase 2b Clinical Trials of R788 in Rheumatoid Arthritis
  
  
• Preliminary Phase 2 Results of R788 in Lymphoma Show Benefit
  
  

• October 27, 2008
  ACR Update Webcast
  Weinblatt ACR Pres. (PDF)
  R788 ACR by Country (PDF)


• Dec 2-3, 2008
  Piper Jaffray Healthcare Conference
  Presenting - Dec. 3, 3:00pm
  
  
• Dec 9-10, 2008
  Merrill Lynch Small Cap Conference
  Presentation - Time & Date TBA